Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Immunovaccine Licenses Clinical Stage Cancer Vaccine from Merck KGaA
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Immunovaccine Inc. announced that it has signed an agreement with Merck KGaA of Darmstadt, Germany, to in-license EMD 640744, an investigational therapeutic survivin-based cancer vaccine designed to target multiple solid tumors and hematological malignancies.
Immunovaccine will build on the current on-going Phase 1 study for EMD 640744 by formulating the survivin-based vaccine in its DepoVax™ delivery system. It is envisioned that after some preclinical work, the EMD 640744-DepoVax combination vaccine will proceed quickly into Phases 1 and 2 of clinical development.
The license agreement grants Immunovaccine exclusive worldwide rights, under issued patents and patent applications, to develop and commercialize the survivin-based vaccine for multiple cancer indications. Under the terms, Immunovaccine will pay Merck KGaA success-based milestones and royalties as a percentage of product sales. Further financial terms were not disclosed.
"Merck KGaA is a global leader with a track record of successfully developing therapies for cancer and we are excited to be working with them on such a vaccine candidate. We look forward to expediting the clinical development of this EMD 640744-DepoVax combination, and expanding Immunovaccine's vaccine pipeline," said Dr. Randal Chase, President and CEO of Immunovaccine Inc.
Immunovaccine will build on the current on-going Phase 1 study for EMD 640744 by formulating the survivin-based vaccine in its DepoVax™ delivery system. It is envisioned that after some preclinical work, the EMD 640744-DepoVax combination vaccine will proceed quickly into Phases 1 and 2 of clinical development.
The license agreement grants Immunovaccine exclusive worldwide rights, under issued patents and patent applications, to develop and commercialize the survivin-based vaccine for multiple cancer indications. Under the terms, Immunovaccine will pay Merck KGaA success-based milestones and royalties as a percentage of product sales. Further financial terms were not disclosed.
"Merck KGaA is a global leader with a track record of successfully developing therapies for cancer and we are excited to be working with them on such a vaccine candidate. We look forward to expediting the clinical development of this EMD 640744-DepoVax combination, and expanding Immunovaccine's vaccine pipeline," said Dr. Randal Chase, President and CEO of Immunovaccine Inc.
